Navigation Links
Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting

ooking statements, which express the current beliefs and expectations of the management of GPC Biotech AG and Pharmion Corporation, including statements relating to results of the SPARC trial and statements relating to the potential efficacy and safety profile of satraplatin. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. In particular, there can be no guarantee that additional information relating to the safety, efficacy or tolerability of satraplatin may be discovered upon further analysis of data from the SPARC trial or analysis of additional data from other ongoing clinical trials for satraplatin. Furthermore, we cannot guarantee that satraplatin will be approved for marketing in a timely manner, if at all, by regulatory authorities nor that, if marketed, satraplatin will be a successful commercial product. We direct you to GPC Biotech's Annual Report on Form 20-F for the fiscal year ended December 31, 2005, Pharmion's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2007, its Annual Report on Form 10-K for the fiscal year ended December 31, 2006, and other reports filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the future results, performance and achievements of either Pharmion or GPC Biotech. Forward-looking statements speak only as of the date on which they are made and neither Pharmion nor GPC Biotech undertakes any obligation to update these forward-looking statements, even if new information becomes availabl
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:10/20/2014)... YORK and RALEIGH, N.C., Oct. 20, 2014 ... Hereditary Neuropathy Foundation (HNF), both philanthropies, announced today ... drug candidates for the treatment of the rare ... BioPontis Alliance announced its alliance model earlier ... a first demonstration of a collaborative model where ...
(Date:10/19/2014)... , Deutschland, October 19, 2014 ... gefragt. Das Problem dabei ist, dass ... mit der Kompetenz zu teilen. Es ... deshalb freuen wir uns umso mehr, dass es ... ihre Gepflogenheiten bei Kühlketten aufzuschreiben - mit einem ...
(Date:10/17/2014)... , Oct. 17, 2014  Hanger, Inc. (NYSE: ... report its results of operations for the quarter ended ... the market closes.  A conference call to discuss these ... on Friday, November 7, 2014. Those wishing to participate ... Friday, November 14, 2014 by dialing 1-855-859-2056 and referencing ...
Breaking Medicine Technology:The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3Vergleichsbericht zu Pharma-Kühlketten und CRT 2
... Oct. 14 PDR Network, the largest distributor ... Risk Evaluation and Mitigation Strategy ("REMS") program alerts, ... largest professional medical liability carrier, to provide physicians ... of REMS CME programs. Physician participation in FDA-mandated ...
... 14 The Food and Drug Administration says ... to treat everything from autism to Alzheimer,s disease—can ... (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo: ... the agency warned eight companies that making unsubstantiated ...
Cached Medicine Technology:PDR Network and The Doctors Company Deliver CME Into REMS 2PDR Network and The Doctors Company Deliver CME Into REMS 3
(Date:10/20/2014)... Columbus, OH (PRWEB) October 20, 2014 National ... Ohio Chapter of the American Academy of Pediatrics (Ohio AAP, ... Administration (NHTSA) in encouraging parents of teen drivers to talk ... hit the road. , Motor vehicle crashes are the leading ... 2,055 teen drivers involved in fatal crashes, and 859 (42%) ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Punzoné , ... in the U.S., has a lot to celebrate this month. ... country recognizes the achievements and contributions of Americans of Italian ... for Punzoné, and today it shares its favorite Italian cocktails ... trip to Italy - even if it is only in ...
(Date:10/19/2014)... October 20, 2014 The leading ... ( http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the best ... platforms for those who want to buy high ... time. , The IT manager of Top10BestSEOHosting.com says, ... most recommended suppliers for everyone. A lot of ...
(Date:10/19/2014)... 2014 Having been working in the garment ... of customer needs. According to James, one of the company’s ... sequins, or with high-low skirts that add beauty to them. ... Recently, LunaDress has unveiled its new selection of 2014 long ... company’s brand new items are available in over 20 popular ...
(Date:10/19/2014)... 19, 2014 Visual Impact Frequency ... just been released to the public generating a ... building and fitness community. The commotion surrounding the ... Vin Delmonico prompting an investigative review. , "Many ... what is commonly known as a training 'plateau' ...
Breaking Medicine News(10 mins):Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2
... a San Francisco Bay Area nonprofit, has been chosen as ... inaugural marathon and 1/2 marathon on June 27, 2009. Becoming ... country can train and prepare for the event and raise ... face of cancer."We are proud to have the honor of ...
... Founder Zac Workman proudly touts support of Sam Schmidt Paralysis ... While Punch Energy Drink,s well-recognized tagline may be "changing the ... beverage industry phenom, is equally focused on changing the world ... , , In a joint press conference today, ...
... Health -- a new suite of affordable healthcare discounts programs that ... out-of-pocket healthcare costs. Reassurance Health offers seven individual and family ... care, and flat-rate reimbursement for doctor visits. , ... ...
... to Cancer Patients in HELIOS HospitalsBERLIN, March 10 ... will gain access to the most modern radiotherapy treatments ... it is acquiring nine linear accelerators from Varian Medical ... them equipped with RapidArc(TM) technology for fast and comfortable ...
... Peripheral Vascular Treatment Market to Grow to $4.7 BillionVANCOUVER, ... international medical device & dental market research firm, an ... lower-limb Peripheral Arterial Disease (PAD), with less than 20% ... increases and more patients seek treatment, the U.S. market ...
... 10 InPlace Medical Solutions recently completed ... healthcare services for Scorpion Offshore Inc.,s ultra-premium ... project makes Scorpion Offshore the first drilling ... full-service system of advanced healthcare, direct physician ...
Cached Medicine News:Health News:Lazarex Cancer Foundation Chosen as an Official Charity of Inaugural Rock 'N' Roll Marathon in Seattle 2Health News:Punch Energy Drink Announces Recipient of Its Inaugural LIVE BETTER AWARD(R) 2Health News:Punch Energy Drink Announces Recipient of Its Inaugural LIVE BETTER AWARD(R) 3Health News:As Layoffs Increase Nationally, Atlanta's Coverdell Launches Suite of Healthcare Discount Programs; Saving Consumers Up to 60 Percent on Healthcare Spending 2Health News:As Layoffs Increase Nationally, Atlanta's Coverdell Launches Suite of Healthcare Discount Programs; Saving Consumers Up to 60 Percent on Healthcare Spending 3Health News:As Layoffs Increase Nationally, Atlanta's Coverdell Launches Suite of Healthcare Discount Programs; Saving Consumers Up to 60 Percent on Healthcare Spending 4Health News:Leading German Healthcare Group Selects Equipment and Software from Varian Medical Systems for Major Replacement Project 2Health News:Study Shows 80% of Adults with Peripheral Arterial Disease Go Undiagnosed 2Health News:Scorpion Offshore Inc. Pilot Project With InPlace Medical Solutions Sets New Standard for Offshore Medical Services 2Health News:Scorpion Offshore Inc. Pilot Project With InPlace Medical Solutions Sets New Standard for Offshore Medical Services 3
... a surgical approach to glaucoma management that ... The ciliary body (which produces aqueous humour) ... anterior or posterior segment, through the endoscope ... easily and accurately identified utilizing endoscopy. This ...
... Endoscopic CycloPhotocoagulation (ECP) is a surgical ... endoscopy and visualized laser application. The ciliary ... by the surgeon, from the anterior or ... time. The target tissues are easily and ...
... surgical approach to glaucoma management that employs ... ciliary body (which produces aqueous humour) is ... or posterior segment, through the endoscope in ... and accurately identified utilizing endoscopy. This allows ...
... a surgical approach to glaucoma management that ... The ciliary body (which produces aqueous humour) ... anterior or posterior segment, through the endoscope ... easily and accurately identified utilizing endoscopy. This ...
Medicine Products: